Apps

openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

IJR News — today's news from every side

Alpha DaRT Pembrolizumab Combo Shows 100% ResponseHealth — Jul 21, 2026Alpha Tau Medical reported positive data from a single-center study of Alpha DaRT combined with pembrolizumab in elderly patients with locally advanced or metastatic head and neck cancer, achieving a 100% systemic objective response rate and an 18.2-month median overall survival with no serious Alpha DaRT-related adverse events. The results, presented at the AHNS conference in Boston, exceeded historical pembrolizumab benchmarks and support continued trials and the company’s strategic push in immuno-oncology, with analyst notes highlighting a Buy rating for DRTS.